Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ: ME )

2.550 +0.080 (+3.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Earnings Scheduled For May 26, 2022
Companies Reporting Before The Bell • American Woodmark (NASDAQ:AMWD) is likely to report quarterly earnings at $1.34 per share on revenue of $493.20 million. 
Via Benzinga
Cramer Says This Stock Is 'Way Too Speculative'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said 23andMe Holding Co. (NASDAQ: ME) is losing money. "To me, buy it and put it away," he commented. 
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
These 5 SPACs All Plummeted After Celebrities Backed Them
Attaching a celebrity's name to a SPAC is a good way to get people excited, but these SPACs all failed despite the support of some big names. 
Via InvestorPlace
Florida Credit Firm Leading Credit Repair Firm in all 50 states.
5 reasons why we are Rated #1 Credit Repair Firm in the United States. Helping Clients all over the 50 states fixing their credit. 
Via IssueWire
7 Badly Bruised Stocks to Buy for the Tough-as-Nails Contrarian
If you loathe groupthink in your investment decisions, these ideas could possibly suit you. 
Via InvestorPlace
23andMe's Q3 Topline Beat Estimates On Boost From Telehealth Business Acquisition
23andMe Holding Co (NASDAQ: ME) has updated its FY22 guidance following the inclusion of telehealth operations into its consumer business.  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
7 Penny Stocks With the Biggest Chance of Blasting Off This Year
Penny stocks can rise quickly on relatively small catalysts, making them a great gamble. Here are a few that should rise. 
Via InvestorPlace
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE: 
Via Benzinga
23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?
Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began... 
Via Benzinga
7 of The Best SPAC Stocks to Put on Your 2022 Watchlist
SPAC stocks may still be out of favor, but you'll still want to keep an eye on these seven picks with merger deals pending. 
Via InvestorPlace
Like Strong Balance Sheets? These 3 Stocks Are Loaded With Cash
With these kinds of resources, these companies are becoming less-risky investments. 
Via The Motley Fool
Why 23andMe Stock Dropped 29% in November
The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks. 
Via The Motley Fool
Why 23andMe Stock Crashed 10% Today
Last week's good news for the genetic data miner wasn't as good as it looked. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Upgrades For Targa Resources Corp (NYSE: 
Via Benzinga
Why 23andMe Stock Scored an 11% Gain Today
23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year? 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Kevin Durant Launching A SPAC That Could Target Sports Or Cryptocurrency
One of the biggest National Basketball Association stars is dipping his toes into the SPAC market, becoming the latest celebrity or athlete to atta... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Why 23andMe Rocketed 27.9% Higher in October
The genetics upstart is acquiring a telehealth platform. 
Via The Motley Fool
November SPAC Merger Calendar: Upcoming Votes, Earnings, Stocks To Watch
The month of November shows a continued slowdown in SPAC merger deal votes, but the calendar includes several multibillion-dollar deals. SPAC merger votes can act as a catalyst,... 
Via Benzinga
These 3 Unique Stocks Have Undeniable Long-Term Upside
These ideas are so unconventional that they just might work. 
Via The Motley Fool
Why 23andMe Stock Was Up More Than 9% on Tuesday
Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid. 
Via The Motley Fool
Why 23andMe Stock Dropped Today
Fresh off its SPAC IPO, 23andMe is buying another company. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
Why 23andMe Stock Has Jumped 16% So Far This Week
A favorable mention on CNBC lit a fire underneath the biotech's stock this week. 
Via The Motley Fool
Jim Cramer Likes CVS And 23andMe, Considers This Stock 'Too Cheap'
On CNBC’s "Mad Money Lightnin... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.